Compare TWAV & INBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWAV | INBS |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | 7 | N/A |
| Industry | Computer Software: Programming Data Processing | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5M | 5.7M |
| IPO Year | N/A | 2019 |
| Metric | TWAV | INBS |
|---|---|---|
| Price | $1.59 | $2.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 80.2K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 68.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,980,484.00 |
| Revenue This Year | N/A | $778.48 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.58 | $0.54 |
| 52 Week High | $2.58 | $24.90 |
| Indicator | TWAV | INBS |
|---|---|---|
| Relative Strength Index (RSI) | 50.98 | 39.12 |
| Support Level | $1.29 | $2.31 |
| Resistance Level | $1.86 | $3.16 |
| Average True Range (ATR) | 0.24 | 0.16 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 24.22 | 22.22 |
TaoWeave Inc is a digital asset company. The company offers investors a regulated, publicly traded vehicle to gain exposure to the decentralized AI economy. The company aims to invest in the Bittensor ecosystem through partnerships with subnets, miners, and validators, and operates with zero debt by maintain appropriate cash reserves. The Company currently operates in three segments: (1) "Digital Assets", which represents the business surrounding treasury activity with Bittensor, (2) Collaboration Products which represents the business surrounding Mezzanine product offerings, and (3) Managed Services, which represents the business surrounding managed services for video collaboration and network solutions.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.